Imbruvica

Blood Cancers

Imbruvica is primarily used to treat adults with certain types of cancer that affect the white blood cells. These conditions include:

• Chronic Lymphocytic Leukemia (CLL): A type of cancer that starts in the bone marrow and moves into the blood.
• Small Lymphocytic Lymphoma (SLL): A cancer that primarily affects the lymph nodes.
• Waldenström’s Macroglobulinemia: A rare type of non-Hodgkin lymphoma that causes an overproduction of certain proteins in the blood.

In some cases, Imbruvica may be used as the first treatment for these conditions, or it may be prescribed after other treatments have been tried. It is sometimes used alone or in combination with other medications, such as rituximab.

Chronic Graft-Versus-Host Disease

Imbruvica is also approved to treat chronic graft-versus-host disease (cGVHD). This is a serious condition that can occur after a stem cell or bone marrow transplant, where the transplanted cells attack the patient's body. It is used for:

• Adults who have already tried one or more other types of systemic therapy without success.
• Children aged 1 year and older who have not responded to previous treatments.

Targeting BTK

Imbruvica belongs to a class of drugs known as kinase inhibitors. Its primary function is to block the activity of a protein called Bruton's tyrosine kinase (BTK).

How it Affects Cancer Cells

BTK is found in B cells, which are a type of white blood cell. In certain types of blood cancers, these B cells grow uncontrollably. BTK sends signals that tell these cells to multiply and stay alive. By binding to and inhibiting BTK, Imbruvica disrupts these signals, which can lead to the death of the cancer cells or prevent them from spreading further in the body.

Use in Graft-Versus-Host Disease

In addition to its role in treating cancer, Imbruvica is used for chronic graft-versus-host disease (cGVHD). In this condition, transplanted immune cells attack the patient's own body. The medication helps by blocking the signaling pathways that contribute to this immune response, potentially reducing inflammation and tissue damage.

Common Side Effects

The most frequently reported side effects of Imbruvica include:

• Diarrhea
• Tiredness or lack of energy
• Muscle, bone, or joint pain
• Rash or itchy skin
• Bruising
• Nausea
• Fever or cough
• Mouth sores

Serious Side Effects

Imbruvica can cause serious complications that may require medical intervention. These include:

• Bleeding: Serious or life-threatening bleeding can occur. Seek help for blood in the stool, pink or brown urine, or coughing up blood.
• Infections: Treatment can increase the risk of severe bacterial, viral, or fungal infections, including pneumonia and sepsis.
• Heart Problems: Some patients develop heart rhythm disorders, such as atrial fibrillation or atrial flutter. Symptoms include palpitations, dizziness, or chest discomfort.
• High Blood Pressure: New or worsening hypertension is common and should be monitored by a healthcare provider.
• Low Blood Cell Counts: Decreases in white blood cells, red blood cells, and platelets are common and can be detected through regular blood tests.
• Tumor Lysis Syndrome: This is caused by the rapid breakdown of cancer cells and can lead to kidney failure or abnormal heart rhythms.
• Second Primary Cancers: New cancers, particularly skin cancers, have been reported in people taking this medication.

Hemorrhage and Bleeding Risks

Imbruvica can cause serious or even fatal bleeding (hemorrhage). The risk of bleeding may be higher in individuals who are also taking blood thinners or antiplatelet medications. Healthcare providers typically recommend stopping the medication for three to seven days before and after planned surgeries to reduce the risk of bleeding complications.

Heart Rhythm Problems

Treatment with this medication has been linked to heart rhythm disorders, such as atrial fibrillation and atrial flutter. These conditions can increase the risk of stroke or heart failure. Monitoring for symptoms like palpitations, dizziness, or shortness of breath is common during therapy, especially in patients with existing heart disease or high blood pressure.

Infections

Serious infections, including bacterial, viral, and fungal infections, have occurred in patients taking Imbruvica. Some of these infections can be life-threatening. Patients are often monitored for fever, chills, or other signs of illness throughout the course of treatment.

High Blood Pressure

New or worsening high blood pressure (hypertension) can occur during treatment. Blood pressure levels should be checked regularly, and new or adjusted blood pressure medications may be necessary to manage this side effect.

Low Blood Cell Counts

Imbruvica can cause a decrease in white blood cells, red blood cells, and platelets (cytopenias). Periodic blood tests are usually required to monitor these levels, as severe drops can increase the risk of infection or bleeding.

Other Major Precautions

• Second Primary Malignancies: There is an increased risk of developing other types of cancer, such as skin cancer or other carcinomas, while taking this medication.
• Tumor Lysis Syndrome: This condition occurs when cancer cells break down quickly, releasing their contents into the blood. It is a medical emergency that requires prompt treatment and monitoring of kidney function and electrolyte levels.
• Embryo-Fetal Toxicity: Imbruvica can cause harm to a developing fetus. Effective birth control is recommended for both men and women during treatment and for a specific period after the final dose. Breastfeeding is generally not recommended during treatment.

Pregnancy Risks

Imbruvica can cause harm to an unborn baby. Research indicates that exposure to this medication during pregnancy may lead to birth defects or pregnancy loss. Healthcare providers typically require a pregnancy test before starting this medication in individuals who are able to become pregnant.

Contraception

To prevent pregnancy during and after treatment, effective birth control should be used:

• Females: Use effective contraception during treatment and for at least 1 month after the final dose.
• Males: Use effective contraception if your partner is able to become pregnant during treatment and for at least 1 month after the final dose.

If you become pregnant or think you might be pregnant while taking this medication, contact your healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known if Imbruvica passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 1 week after the last dose.

Available Forms

Imbruvica is administered orally and comes in the following forms:

• Capsules: Hard-shell capsules for oral use.
• Tablets: Film-coated tablets for oral use.
• Oral Suspension: A liquid formulation used for oral administration.

The oral suspension is used for certain patient populations, including pediatric patients, and provides an alternative for those who may have difficulty swallowing solid dosage forms.

FDA Approval History

Imbruvica was first granted FDA approval in 2013. Over the following years, the FDA expanded its approved uses to include several types of B-cell malignancies and chronic graft-versus-host disease (cGVHD). In 2022, the FDA approved the drug for pediatric patients aged 1 year and older with cGVHD, which included the introduction of an oral suspension formulation.

Current Approved Indications

As of the most recent regulatory updates, Imbruvica is FDA-approved for the treatment of:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
• Waldenström’s macroglobulinemia.
• Chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy.

In 2020, the FDA specifically approved the combination of ibrutinib with rituximab for the treatment of previously untreated patients with CLL or SLL.

Regulatory Status Changes

While Imbruvica previously held accelerated approvals for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), the manufacturer voluntarily withdrew these indications in 2023. This decision followed results from confirmatory clinical trials that did not meet the requirements to convert the accelerated approvals to full approvals.

Insurance and Prior Authorization

Imbruvica is a specialty medication, which means it is often more expensive than standard prescriptions. Most insurance plans, including Medicare and private insurance, require prior authorization before they will cover the cost. This process involves your doctor providing documentation to the insurance company to prove the medication is medically necessary.

Financial Assistance Programs

Because of the high cost of this treatment, there are several options that may help reduce out-of-pocket expenses:

• Manufacturer Co-pay Cards: Patients with commercial insurance may be eligible for co-pay savings programs provided by the drug manufacturer.
• Patient Assistance Programs: For individuals without insurance or those who are underinsured, non-profit foundations or the manufacturer may offer programs to provide the medication at a lower cost or for free.
• Specialty Pharmacy Services: Since Imbruvica is usually dispensed through specialty pharmacies, these providers often have staff dedicated to helping patients navigate insurance claims and find financial aid.

It is important to discuss financial concerns with your healthcare provider or a social worker, as they can help identify resources to assist with the cost of therapy.